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Background: Adherence is a critical component of clinical intervention utility, but little is 
known about how cancer patients with depression, particularly low-income, ethnic minority 
patients, perceive adherence to and drop out from treatment.
Aim: To explore low-income, minority cancer patient perspectives about not adhering or drop-
ping out of depression treatment.
Methods: A qualitative substudy was conducted within the Alleviating Depression among 
Patients with Cancer (ADAPt-C) study. The intervention was an individualized stepped care 
depression treatment program provided by a clinical social worker in collaboration with a study 
psychiatrist. Patients randomized to the intervention were offered antidepressant medication 
and/or 8–10 sessions of problem solving treatment talk therapy. In-depth telephone interviews 
were conducted with 20 patients who had dropped out of depression treatment, using a grounded 
theory qualitative methodological approach.
Results: Enrolled intervention patients were predominately Latina, Spanish-speaking, and 
  foreign born. Most patients (12/20) acknowledged they had dropped out of treatment for a variety 
of reasons, including dissatisfaction with treatment, poor patient-provider relations, logistical 
and financial barriers, cancer treatment commitments, and language barriers. However, other 
patients (8/20) denied they had dropped out of treatment and/or became confused about being 
labeled as a “dropout.”
Conclusion: A substantial percentage of low-income, ethnic minority patients who drop out 
of treatment for depression appear not to realize they have dropped out of treatment. Improving 
treatment adherence requires explanation of what constitutes adherence and the consequences 
of failing to do so from the perspective of both patient and provider.
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Introduction
Little is known about adherence among cancer patients with depression,1–3 particularly 
patients from hard-to-reach backgrounds such as racial/ethnic minority and low-
income patients. Most attention has been directed to treatment success rather than 
to drop out, refusal, or relapse after treatment.4 Adherence is a critical component of 
clinical intervention utility; if patients do not utilize the intervention, it can become 
super  fluous, even with strong evidence of efficacy.5
Although a great deal of research has been conducted on factors related to adher-
ence to depression treatment in general,6 few studies have examined the phenomenon 
of dropout from cancer treatment among cancer patients.7–11 Based on a systematic 
review of depression treatment studies with cancer patients, we know that dropout Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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rates in controlled psychotherapy trials can range up to 
41%.12 Nonadherence to depression treatment is even a 
major obstacle in the retention of patients with cancer in 
clinical trials.13 It was reported that side effects associated 
with antidepressants lead to discontinuation of therapy or a 
lack of patient compliance, with twice as many clinical trial 
patients discontinuing treatment because of side effects.14 
Some patients who discontinue therapy report that they were 
not interested in involvement because they believed the medi-
cation was not working, that they were feeling better, or that 
they did not need the medication.15,16 Other known barriers 
to treatment include side effects from both chemotherapy,17–20 
antidepressant medication treatment,14,21 fatigue,22 cognitive 
impairment,23 and delirium.24
Part of the challenge of studying adherence and dropout 
is that these phenomena are variably defined,1,25–28 typically 
by providers29,30 rather than patients. Although some studies 
have examined patients’ reasons for dropout, the explanations 
are brief and vaguely described. In-depth patient perspectives 
are critical because such patients may fail to engage in and 
accept treatment for a variety of reasons rooted in their own 
cultural background and personal experiences,31 which are 
important to understand in order to develop strategies for 
reducing the rate of drop out.
This study examined the perceptions of treatment 
  adherence and dropout in a sample of low-income, minority 
(predominately Latina) depressed cancer patients, who have 
been historically unrecognized in the clinical oncology litera-
ture. Using former participants from a randomized clinical 
depression treatment trial of cancer patients –   Alleviating 
Depression among Patients with Cancer (ADAPt-C)32 – 
the parent study explored barriers and factors associated 
with depression treatment non-adherence and dropout. 
  Specifically, this study aimed to explore low-income, minor-
ity cancer patient perspectives about not adhering or dropping 
out of depression treatment.
Methods
A qualitative substudy was conducted within the ADAPt-C 
study.32 The intervention was an individualized stepped 
care depression treatment program provided by a cancer 
depression clinical specialist in collaboration with a study 
  psychiatrist. Patients were randomized to intervention or 
usual care via the recruiter providing the patient with a 
choice from five sealed envelopes that contained one sheet 
of paper indicating a study group randomly determined by 
computer algorithm. Patients randomized to the interven-
tion were offered antidepressant medication and/or problem 
solving treatment (PST), a cognitive-behavioral treatment 
which has been found   effective in treating depression among 
Latinos, particularly when socioenvironmental stress is a sig-
nificant factor.33–36 The initial intervention visit(s) included: 
semistructured psychiatric/psychosocial assessment; patient 
depression, psychotherapy, and antidepressant education; 
consideration of initial treatment choice; provision of patient 
navigation assistance; and included family members at 
patient’s request. Subsequent visits provided structured PST 
and/or antidepressant medication monitoring. Active PST was 
designed to last 8–10 sessions. Homework materials were 
linguistically and idiomatically adapted. After acute treat-
ment, patients received a treatment maintenance and relapse 
prevention program, including cancer depression clinical 
specialist monthly telephone contacts up to 12 months after 
treatment initiation to monitor symptoms (with additional 
in-person visits if indicated), behavioral activation support 
for engaging in pleasant activities, and motivational support 
for ongoing use of PST skills and medication adherence.
ADAPt-C parent grant inclusion criteria included adult 
cancer patients $90 days from a cancer diagnosis who were 
receiving acute treatment or follow-up care in oncology 
clinics, but did not have advanced cancer or another medical 
condition that limited remaining life expectancy to less than 
6 months.37 PST dropouts were defined as patients who had 
fewer than four PST sessions. PST dropouts included those 
who initially agreed to be randomized to the intervention, 
but thereafter had either verbally declined treatment or did 
not show up for the appointments. This included patients 
who had refused some sessions, but agreed to remain in the 
study for outcome interviews. Patients who died or were 
unable to be reached were not considered to be dropouts. 
Patients receiving antidepressant medication were dropouts 
if they discontinued treatment within 30 days, which is the 
benchmark used for determining adherence to antidepres-
sant medication.7 For antidepressant medication treatment, 
patients could have refused further medication, but initially 
agreed to complete ADAPt-C parent grant outcome inter-
views and receive gift card incentives. In this study, we 
operationalized “adherence” to treatment as four or more 
PST sessions and continuing antidepressant medication for 
more than 30 days.
Twenty of the 39 patients (51.2%) eligible to participate 
in the study agreed to do so. Informed consent was obtained 
from each patient in accordance with procedures approved 
by the Institutional Review Board of the University of 
Southern California. Recruitment material and scripts were 
sensitive to, and addressed the fact, that these individuals Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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decided against continuing in a prior research study. It was 
possible that they could continue to decline to participate 
in this smaller research study as well. The materials made 
it unequivocally clear that they were being invited to par-
ticipate in a research study because they had not continued 
in a prior research study. Responses to the interview guide 
protocol were obtained through an iterative process within 
each interview, or across interviews, consistent with the 
nature of qualitative research.38 The first phase of dropout 
data collection involved in-depth minimally structured 
individual telephone interviews. Participants were recruited 
by telephone from culturally trained bilingual recruiters. To 
strengthen data accuracy, researchers conducted more than 
one interview. Interviews averaged 1 hour in length and 
were digitally recorded and later translated into English and 
transcribed for analysis.
Using a methodology of “coding consensus, co- 
occurrence, and comparison”39 and rooted in grounded 
  theory, all transcripts were analyzed using ATLAS.ti 
(ATLAS.ti Scientific Software Development GmbH, Berlin, 
Germany). Segments of transcripts were assigned codes 
based on a priori theory of planned behavior,40,41 sensitizing 
concepts (ie, questions in the interview guide) with emphasis 
on cultural explanatory model of illness,42 or emergent (ie, 
issues raised by the respondents themselves) themes.40
Results
Of the 242 patients who were enrolled in the ADAPt-C 
depression treatment intervention participation, 152 satis-
fied the criteria of adhering to treatment while 90 patients 
met the criteria for withdrawing or dropping out of 
  treatment. Dropouts were predominately female (90%), 
Latino (85%), foreign-born (80%), unmarried (55%), 
unemployed (85%), .50 years old (65%), and in the United 
States .10 years (80%). Forty percent of sample had less 
than a 12th grade education. With regard to depression 
characteristics, most patients in the sample had moderate 
depression levels (80%). One of the two dropout patients 
who were prescribed antidepressant medication was taking 
Lexapro® (10 mg daily); the antidepressant medication that 
the other patient was prescribed is not known. Regarding 
cancer characteristics, most of sample was diagnosed with 
a less advanced cancer stage (70%) and were in follow-up 
cancer treatment (70%). Only 20% of this sample described 
pain. Interestingly, 45% of this sample complained of 
comorbid medical problems. All dropout and completer 
characteristics were similar to the overall parent grant 
characteristics.
This study’s dropout recruitment efforts occurred 
between early January and mid-March 2008. At the time of 
recruitment for this study, there were 39 parent study drop-
outs who initially completed the baseline assessment and 
were randomized to the intervention. Of these 39   participants, 
19 were still not able to participate for the following reasons: 
moved (n = 1), disconnected telephone number (n = 5), 
changed telephone number (n = 1), unable to be reached by 
telephone (n = 10), or died (n = 2). However, of the remaining 
20 dropouts who were able to be reached, all were willing 
to participate.
It is important to look first at the term “dropout” to gain 
insight into how patients conceptualized the act of terminat-
ing their participation. Initial interviews with dropouts began 
with an inquiry about their definition and description of the 
term. However, in subsequent interviews, the interviewer 
was cautioned about using the word “dropout” during the 
interview, as this word had the potential to have negative 
connotations to the patient and/or might not have accurately 
reflected the patient’s status according to their individual 
perspective. Instead, interviewers were advised to refer to 
dropout as “discontinuing treatment.”
Patient interviews were characterized by definitive state-
ments such as, “I decided to stop the treatment.” Twelve of the 
20 patients interviewed acknowledged that they had dropped 
out of treatment, citing several reasons and circumstances 
related to dropping out of treatment. These included the 
following: cancer-related (which included the emotional 
impact of the cancer diagnosis [n = 20] and cancer treatment 
commitments [n = 11]), depression treatment-dissatisfaction 
(n = 9), informational (which included study misunderstand-
ings [n = 6]), instrumental (which included transportation 
problems [n = 14], financial issues [n = 11], employment-
related concerns [n = 11], and caregiving demands [n = 3]), 
cultural (which included language communication problems 
[n = 7] and discrimination from providers [n = 5]), and 
systems-related (which included service-related logistical 
issues [n = 13] and patient-provider problems [n = 10]). These 
barriers were not mutually exclusive; instead they were often 
described in combination (Unpublished data, 2011).
The remaining eight patients either disagreed that they 
had dropped out of treatment, perceived the term to be mis-
leading because it implied a willful or voluntary response to 
an uncontrollable situation, or were confused by the term and 
uncertain as to whether it applied to their own situation. For 
example, one participant said, “Did I dropout? No, I didn’t 
dropout. I became busy and I figured I started missing calls.” 
Similarly, another said, “Like I have repeated, I didn’t stop Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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any treatment.” Another participant expressed that she had 
not chosen to dropout so therefore was not comfortable with 
this label, “It wasn’t dropping out because I didn’t not want 
to get help … It’s not like it was under my power. You know 
what I mean? You can say [dropout] if you want to but I don’t 
feel like I want[ed] to get out of the study.” Similarly, another 
participant thought the label sounded negative, “I think that I 
dropped out but I don’t know – it does not sound good.”
Some participants did not understand what was being 
asked and called the question “weird;” one participant said 
that her continuation with other treatment meant that she had 
not dropped out. One participant said, “I don’t know what to 
tell you. I’m confused. I can’t answer that question. You can 
ask me a thousand times. I can’t answer it.”
Discussion
In this study, the majority of low-income, ethnic minority 
cancer patients identified as having discontinued treatment 
for depression acknowledged that they had indeed “dropped 
out” of treatment. Their reasons for doing so are consistent 
with barriers cited in other studies of adherence to depression 
treatment. However, this study also revealed that the label 
of “dropout” is not always true to the patient’s perspective 
on discontinuation of depression treatment, and in fact is 
sometimes contrary to the patient’s understanding of what 
occurred. Some patients denied dropping out of treatment, 
asserting that they were continuing to receive services. Other 
patients suggested the term did not accurately reflect their 
decision to leave treatment because it implied a voluntary 
action when their own perception was that the act of with-
drawing from treatment was anything but voluntary. Still 
other patients were confused by the term and unsure as to 
whether or not they were still in treatment.
Although not specifically mentioned by any of the 
participants in this study, a potential reason for failing to 
acknowledge treatment dropout might be that patients got 
all they needed out of the treatment and were satisfied with 
the treatment they received. From a research perspective 
they dropped out of treatment, but from a phenomeno-
logical perspective, they completed what they needed to 
complete. Another reason may have been that some patients 
may not have been able to remember the sequence of events 
leading up to their discontinuation. Also, some patients may 
have, in fact, been currently in treatment with another 
provider so they may have perceived themselves to still be 
in treatment, even though they were not technically in the 
treatment program to which they had consented. Due to 
the potentially negative and/or   stigmatizing connotation of 
the term (eg, “high school dropout”), it may be important 
in future studies to choose alternative terminology or to at 
least approach patients who discontinued treatment with 
a more exploratory approach regarding their   decisions. 
An alternative term which has received increased usage 
over the past decade or so is “concordance”, which is 
described as a more equal relationship between physician 
and patient.43
There are several limitations to our study that deserve 
mention. First, study participants were not selected at ran-
dom from the group of ADAPt-C participants who satisfied 
criteria for dropout status and thus may not be representative 
of the broader population of low-income, minority cancer 
patients who withdraw from treatment. Thus, the results 
obtained may not generalize to either population. Second, 
as a qualitative study, both collection and interpretation of 
data is susceptible to subjective bias and preconceived ideas 
of the investigators. Third, there might have also been trans-
lational issues, with the term “dropout” not being directly 
translatable into Spanish. Finally, we did not investigate the 
potential influential roles of type and tolerability of antide-
pressant medication and/or cancer treatment in adherence to 
depression treatment.
Conclusion
Improving adherence to treatment for depression among 
low-income, ethnic minority cancer patients requires more 
than addressing known barriers to treatment such as language 
and cultural differences, lack of transportation and health 
insurance, and dissatisfaction with care received. It also 
requires an understanding of how patients define adherence 
and dropout or withdrawal from treatment. Embedded within 
these definitions are rationales for decisions and behaviors 
that may be interpreted by providers as lack of adherence, 
but interpreted by patients as either evidence of adherence or 
an involuntary action that represents neither adherence nor 
dropout. Understanding the motives underlying such invol-
untary actions or the rationale for describing such actions 
as evidence of adherence is essential to developing patient 
education programs and psychoeducational interventions 
that can improve adherence to depression treatment in this 
medically underserved population. In addition, it is important 
to consider the important role of social support (ie, family, 
healthcare providers), as a vehicle for helping to interpret 
and facilitate communication for depressed cancer patients. 
Family, friends, and healthcare providers can provide valu-
able emotional and instrumental support to help facilitate 
treatment adherence.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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